AstraZeneca to pay $5.52 mln to resolve US SEC foreign bribery case

US regulators said on Tuesday that AstraZeneca Plc will pay $5.52 million to resolve a foreign bribery probe into improper payments by its sales and marketing staff to officials at state-controlled health care providers in China and Russia.
The US Securities and Exchange Commission detailed the settlement with the drug company in an order instituting an administrative proceeding arising out of violations of provisions of the Foreign Corrupt Practices Act.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy